We hear this, and we understand the concern. But the reality is that large-scale outcome trials often suffer more from large-CRO operational drag — governance delays, staff turnover, and handoffs — than from lack of scale. We deliver leaner, smarter Phase III execution with a global footprint across our established site network. And we can prove it: we’ve operationalized complex, multi-country Phase III programs through our PHP network with measurably less friction.

That’s exactly where we excel. Our lean governance structure means your decisions reach execution in days, not months. When every minute matters, we move at the speed your program requires.

MACE endpoint adjudication is critical for cardiovascular outcome trials, and we take it seriously. Our teams have direct experience with clinical event committee coordination, blinded adjudication processes, and the regulatory scrutiny that follows. We also maintain relationships with the specialty imaging and diagnostic vendors required for cardiac imaging endpoints.

Cardiovascular trials are long. Retention periods can span years, and mid-trial staff turnover is devastating. Our CV teams have long tenure and stable leadership, meaning your project lead at kickoff is your project lead at database lock.

CKM syndrome is one of our specializations. We design endpoints across the cardiovascular-kidney-metabolic continuum, integrating cardiac, renal, and metabolic outcomes into protocols that reflect the real-world complexity of these patient populations. Our multidisciplinary teams include CV, renal, and metabolic specialists who collaborate across indications.